

# Unveiling sex-based differences in Parkinson Disease: a comprehensive meta-analysis of transcriptomic studies

Adolfo López-Cerdán<sup>1,2†</sup>, Zoraida Andreu<sup>3†</sup>, Marta R. Hidalgo<sup>1</sup>, Rubén Grillo-Risco<sup>1</sup>, José Francisco Català-Senent<sup>1</sup>, Irene Soler-Sáez<sup>1</sup>, Almudena Neva-Alejo<sup>1</sup>, María de la Iglesia-Vayá<sup>2</sup>, Francisco García-García<sup>1</sup>

<sup>1</sup>Bioinformatics and Biostatistics Unit, Príncipe Felipe Research Center (CIPF), 46012, Valencia, Spain

<sup>2</sup>Biomedical Imaging Unit FISABIO-CIPF, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana, 46012, Valencia, Spain

<sup>3</sup>Foundation Valencian Institute of Oncology (FIVO), 46009, Valencia, Spain

## Abstract:

At present, Parkinson's disease (PD) is the fastest growing neurodegenerative disease in the older population. Increasing longevity, aging populations, declining smoking rates, and increasing industrialization are responsible for this rapid growth. Sex has been described an important variable to consider in this disease as risk of developing PD, symptoms, treatment response and mortality differ between males and females. We have conducted a systematic review and individual meta-analyses in the main brain areas affected by PD: frontal cortex (FC), striatum tissue (ST), and substantia nigra (SN). A fourth meta-analyses that integrated the data of the three regions to analyze sex differences in PD also was performed. We selected seven studies focused on PD and with sex information from 83 non-duplicated studies. A total of 267 samples have been analyzed (132 controls, 51 females and 81 males; and 135 cases, 58 females and 77 males). The individual meta-analysis showed no significant genes in FC but one gene (MED31) was upregulated in females in ST and 237 genes appeared significantly dysregulated in SN (162 up in females and 65 up in males). The global meta-analysis that integrated FC, ST and SN (seven studies), detected fifteen genes differentially expressed by sex (four up in females; eleven up in males). These genes were involved in mitochondrial function, neuronal lesions, intracranial hemorrhage and intellectual disability. It is the first time that these genes are related to PD sex-based differences. Finally, a functional enrichment analysis based on the 237 genes differentially

expressed in SN evidenced that although the final result is similar for males and females (oxidative stress, neuronal degeneration and death) the pathways involved, the protein-protein interaction networks, even the transcription factors that regulate them, differ by sex. Males present an overrepresentation of functions related to oxidative stress based on ion metals, and functions related to inflammation and angiogenesis. While females presented dysfunctions in mitochondrial and lysosomal activity, processing and antigen presentation functions, glutamic and purine metabolism, mainly. These data could contribute to better knowledge of PD with sex perspective and highlights the importance of including the sex factor in research studies.

## 1. Introduction

Parkinson's disease (PD) is the second progressive neurodegenerative disease after Alzheimer's that mainly affects individuals with a prevalence of 1% (over 65 years of age) and 2% (those over 85 years of age) [1]. There are some cases of PD in younger ages (4th decade of life, 1 in 250) [2]. PD affects specific areas of the brain such as frontal cortex (FC) involved in mental tasks; striatum tissue (ST) that coordinates multiple aspects of cognition, including both motor and action planning, decision-making, motivation, reinforcement, and reward perception; and substantia nigra (SN): an important player in eye movement, motor planning, reward-seeking, learning, and addiction. Many of the SN effects are mediated through the ST, in fact the absence of dopamine by the selective degeneration of dopaminergic neurons located in the SN that innervate the ST (nigrostriatal dopamine system (NSDA)) and the formation of Lewy bodies ( $\alpha$ -synuclein accumulation in neurons) [3] are responsible of motor problems including resting tremor, muscle stiffness and bradykinesia, postural instability as well as non-motor symptoms (cognitive and mood impairment, smell, and autonomic dysfunctions). In advanced stages of the disease a third of patients develop dementia [4]. Oxidative stress, excitotoxicity and neuroinflammation influence neuronal death in PD [5], [6]; nitric oxide (NO) and other reactive nitrogen species [7], [8] promote PD progression. Additionally, mitochondrial dysfunction has an important role in PD as in other neurodegenerative diseases [9]. At present, the etiology of PD remains unclear but a combination of genetic factors and environmental triggers seem to play a role, including the following: genetic variations, sex, aging, exposure to toxins as herbicides and pesticides [10].

Male and female present sex-related differences in PD [11]. PD is more common in males than in females (ratio of 2:1, approximately) and the PD risk is higher in males [12], but a greater mortality and earlier nursing home placement is documented by females [13]. Besides, sex-related differences in the nigrostriatal degeneration, in the symptoms onset, in the motor and non-motor symptoms, in the REM sleep behavior disorder, in the treatment outcomes, and in the mechanisms involved in PD as inflammation and mitochondrial function has been described in PD [14]–[18]. General genetic factors, sex chromosomes genes, hormones and neuroactive steroid point to the main causes for sex related differences in PD [15], [18], [19]. While sex differences on inflammation and sex differences on mitochondrial function represent mechanisms involve in PD differences among sexes [20], [21]. A minority of PD cases can benefit from genetic testing but no daily clinical method exists for the diagnosis of PD *in vivo*. Additionally, making a definitive diagnosis at the earliest stages is a challenge that complicates the management of symptoms at later stages. Although therapeutic options such as levopoda and deep brain stimulation improve the symptoms and the quality of life of the patients, the treatments do not delay the neurodegenerative process. Identifying biomarkers is an

unmet task for early diagnosis and creating better therapies to improve the treatment of non-motor symptoms and motor complications.

To evaluate sex related patterns in PD, we have performed a systematic review and four meta-analyses of transcriptome studies that included information on patient sex from Gene Expression Omnibus (GEO) [23] and ArrayExpress databases [24]. One meta-analysis for each of the major brain regions affected by PD pathogenesis: FC with three studies, ST with three studies and SN with four studies. The fourth meta-analysis included the 3 brain regions together FC, ST, SN, with a total of seven studies. The differential gene expression analysis (DGEs) showed only one gene differentially expressed in ST but 237 genes appeared dysregulated by sex in SN (75 more expressed in males and 162 genes more expressed in females). No gene appears differentially expressed in the FC when we compare male cases with female cases. Additionally, the meta-analysis of all studies together evidenced 15 genes differentially expressed between sexes, almost all involved in neural and intellectual disorders as indicated in Open Targets (OT) platform [25]. Focus on SN, the major region involved in PD, a functional signature performed based on 237 genes revealed that genes up in males were related to metallothioneins, apolipoproteins and interferon induced transmembrane proteins while in females were related to secretogranins, V-ATPase, subunits TIM22 complex subunits, cytoskeletal and axon transport proteins, mitochondrial porins, glutamic-oxaloacetic transaminases and serine threonine phosphatases, closely related to neurodegeneration and neuronal death. Therefore, males and females with PD showed stress oxidative, neuroinflammation and neuronal death as common scenarios but the genes and mechanisms involved differ between sexes. Moreover, our meta-analysis has identified several transcription factors dysregulated in males and females that open new perspectives for early diagnosis in PD. Finally, we have explored in the OT platform if the significant genes identified in our revision based on sex differences in PD have been ready PD-linked genes. Certainly, some of the identified genes appeared as PD-linked genes in OT and many others associated with other neurodegenerative and intellectual disorders giving robustness to our meta-analysis but it is the first time that these genes are sex related in PD. Interestingly, we have also found novel genes never before associated with PD and sex related. We hope contribute to a better understanding of PD taking into account sex differences and provide useful information, opportunities and challenges for further studies, diagnosis and novel therapeutics approaches of PD according to the needs of males and females.

## 2. Results

We showed finding setup into three sections: i) a description of the studies evaluated and selected in the systematic review; ii), individual bioinformatic analysis of each selected studies that include an exploratory analysis and the differential expression analysis; iii) the results of the integrated differential transcriptomics and functional profiling by sex.


### 2.1. Study Search and Selection

The systematic review identified 83 non-duplicated studies, of which 46.98% included both male and female patients. After a more exhaustive revision with inclusion and exclusion criteria (see **Figure 1**), we selected a set of 34 comparable studies to ensure the reliability of the subsequent analyses. Of these 34 selected studies, only 8 were focused on Parkinson's and fulfilled the homogeneity criteria of the experimental design. Finally, and after the exploratory analysis, one study was discarded, leaving seven studies for the final analysis that included the main brain areas affected by PD: FC, ST and SN (**Table 1**). The selected studies represented 267 samples (132 controls and 135 cases), of which 59%


were from males and 41% from females (**Figure 2**), with a median age of 75 years old. **Table 1**, **Figure 2**, and **Supplementary Table S1** contain further information regarding the selected studies and the clinicopathological characteristics of the study population.

**Table 1.** Studies selected after the systematic review. Brain areas: cortex frontal (FC), striatum tissue (ST) and substantia nigra (SN).

<b>Study</b>	<b>Platform</b>	<b>Brain area</b>	<b>Publication</b>
E-MTAB-1194	Affymetrix GeneChip Human Gene 1.1 ST Array	FC	[26]
E-MEXP-1416	Affymetrix GeneChip Human X3P Array	SN	[27]
GSE8397	Affymetrix Human Genome U133A Array	SN	[28], [29]
GSE20295	Affymetrix Human Genome U133A Array	FC, SN, ST	[30], [31]
GSE7621	Affymetrix Human Genome U133 Plus 2.0 Array	SN	[32]
GSE20146	Affymetrix Human Genome U133 Plus 2.0 Array	ST	[31]
GSE28894	Illumina HumanRef-8 v2.0 Expression Beadchip	FC, ST	-



**Figure 1.** Flow of information through the different phases of the systematic review, following PRISMA Statement guidelines [33].



**Figure 2.** Number of samples per study, divided by sex and experimental group (PD – Parkinson's Disease samples).

## 2.2. Individual Analysis

Even though normalized data were retrieved from all the selected studies, we carried out exploratory and processing steps for the data set to ensure the comparability and integration of subsequent analyses. In some cases (GSE28894, GSE20295, GSE7621 and GSE20146), logarithm 2 data transformation was applied in order to homogenize magnitude order between studies. Only samples from the selected brain regions were considered. Lastly, exploratory analysis revealed an anomalous behavior (outlier) by A04022 sample from E-MTAB-1194 study. This sample was excluded for further analysis.

The differential expression results for each study showed a large number of differentially expressed genes when comparing female Parkinson's disease patients to female control patients (PD.W - Control.W) and male Parkinson's disease patients to male control patients (PD.M - Control.M) (**Supplementary Table S1**). However, the evaluation of sex-based differences in Parkinson's disease patients, through the contrast (PD.W - Control.W) - (PD.M - Control.M), provided only a small number of significantly affected genes in the GSE8397 study (**Table 2 & Supplementary Table S1**). This data highlights the need of more statistical power approaches to decipher more subtle biological differences between groups.

**Table 2.** Summary of differential gene expression analysis results by brain region in sex contrast. "Up" genes are overrepresented in female PD patients, while "Down" genes are overrepresented in male PD patients. The dash "-" indicates the absence of results due to the lack of that tissue in that study.

	Significant Genes Cortex			Significant Genes Striatum			Significant Genes Substantia Nigra			Significant Genes All tissues		
	Up	Down	Total	Up	Down	Total	Up	Down	Total	Up	Down	Total
E-MTAB-1194	0	0	0	-	-	-	-	-	-	0	0	0
E-MEXP-1416	-	-	-	-	-	-	0	0	0	0	0	0
GSE8397	-	-	-	-	-	-	30	65	95	30	65	95
GSE20295	0	0	0	0	0	0	0	0	0	0	0	0
GSE7621	-	-	-	-	-	-	0	0	0	0	0	0
GSE20146	-	-	-	0	0	0	-	-	-	0	0	0
GSE28894	0	0	0	0	0	0	-	-	-	2	0	2

### 2.3. Gene Expression Meta-Analysis

Given that, the major brain regions involved in PD are FC, ST and SN; we performed a gene expression meta-analysis in each of these regions based on the data set of three studies for FC, three studies for ST, and four studies for SN. Finally, we performed a global meta-analysis that integrated all studies from the three major brain regions (FC, ST, SN, 7 studies in total). In the meta-analysis by regions no significant genes were found in FC, while only **MED31** (mediator of RNA polymerase II transcription subunit 31) gene showed significant differential expression in ST. In SN, 237 genes were significantly dysregulated, finding that correlates with the fact that this region is the major region affected by PD. 75 genes exhibited a higher expression pattern in male and 162 were more expressed in females (Table 3).

**Table 3.** Meta-analysis results in substantia nigra. Significant genes are specified by sex. Genes with a documented association with PD in OpenTargets database (OT) are highlighted in bold type.

Over-expressed in	Significant genes
Male	<b>ABCB1</b> , ACADS, ANP32B, <b>ANXA2</b> , APOBEC3C, APOC2, APOL1, ARPC1B, ATAD3A, ATP5J2-PTCD1, <b>CA5A</b> , <b>CACNA1A</b> , CALHM2, <b>CFB</b> , CLASRP, CLIC1, CSPG4, CYBA, DNAJC1, <b>ENG</b> , FAM107A, FBXO16, FKSG49, GPR4, <b>GTF2H4</b> , HBD, HLA-E, <b>HSPG2</b> , HYAL2, ID3, IFITM2, IFITM3, IGFBP7, INPPL1, ITGA5, <b>KANK2</b> , KCNT1, KCTD12, KLK4, LAMA5, LIMS2, LOC100132686, LOC101928717, LRRC32, MEGF6, MICALL2, MIR6513, <b>MT1E</b> , MT1M, <b>MT2A</b> , NME4, NUPR1, OPLAH, PACSIN3, <b>PDGFRB</b> , <b>PNMT</b> , POLR1E, PTGDR2, PTP4A3, P XK, RAB13, <b>RALGDS</b> , <b>RBM38</b> , RP4-781L3.1, RPL27A, <b>SH2B2</b> , SPATA2L, STARD3, STOM, TARP, TMSB10, TNXA, TRIOBP, ZNF296, ZRSR2
Female	<b>ACOT7</b> , ACTR10, ACTR3B, ADAM23, AK5, <b>AKAP11</b> , <b>ALDH1A1</b> , ALG6, AMPH, APOO, ARF3, ARMCX2, ARMCX5, ATP5B, <b>ATP6AP1</b> , ATP6V0D1, ATP6V1B2, ATP6V1E1, <b>ATP6V1G2</b> , ATP8A2, <b>ATXN10</b> , B3GALNT1, B4GALT6, BEX1, BEX4, BHLHB9, <b>C9orf72</b> , C10orf88, C12orf4, <b>CADPS</b> , CCDC113, CERK, <b>CHCHD2</b> , <b>CHGB</b> , <b>CLTC</b> , CSTF3, <b>DCLK1</b> , DCTN3, DCTN6, <b>DLAT</b> , DPY19L2P2, DYNC1I1, DYNC1LI1, DYNLL1, EEF1E1, ELOVL6, <b>ENPP2</b> , <b>ERC2</b> , F8A1, FAM127A, FAM188A, FDX1, FHOD3, <b>GABARAPL2</b> , GBP6, GLRB, <b>GOT1</b> , GOT2, GPRASP1, GRSF1, HDHD2, HN1, <b>HPRT1</b> , <b>HSPA8</b> , KIF2A, KIFAP3, KLHL26, LAPTM4B, LCMT1, LOC101930324, <b>LRPPRC</b> , LRRC49, MAN2A2, MAP1LC3B, MAP2K4, <b>MDH1</b> , MEAF6, MIA3, MORF4L1, MRPL15, MTMR4, MTX2, MYO5A, NARS2, <b>NDFIP1</b> , <b>NDN</b> , NECAP1, NELL2, NGFRAP1, NIPSNAP3B, <b>NME1</b> , <b>NSG1</b> , NUP93, <b>OCRL</b> , OGFOD1, <b>OPA1</b> , <b>OPTN</b> , OXCT1, <b>PCMT1</b> , PEX11B, PFN2, <b>PGAM1</b> , PI4KA, PPP2CA, <b>PPP3CB</b> , PRPS1, <b>PTPN5</b> , <b>PTS</b> , PSMB5, PSMB7, RAD17, RAN, RBKS, RCAN2, REEP1, REEP5, RFK, RNFT2, RRAGA, <b>SCG2</b> , <b>SCG3</b> , SCG5, SHROOM2, SLC25A14, <b>SLC25A3</b> , SLC38A6, SMIM8, SMPX, SNAP91, SNX16, <b>SOD1</b> , SPA17, <b>SPINT2</b> , STAT4, TAGLN3, TBC1D30, <b>TERF2IP</b> , THAP10, TIMM10B, TIMM8B, TMEM246, TMEM35, TMX2, TOMM70A, TSPYL5, TTC1, TUBA1B, TUBA3C, TUBB4B, <b>UBB</b> , UBXN8, <b>UCHL1</b> , <b>UQCRF51</b> , VAV3, VDAC2, VDAC3, <b>VPS41</b> , VSNL1, <b>YWHAG</b> , WASF3, ZNF204P, ZNF667

The global meta-analysis that integrates the seven studies and the three main regions affected by PD showed fifteen genes differentially expressed by sex (four up in female; eleven up in male) (Table 4). In male the upregulated genes included: **AC073283.7** (a long non coding RNA), **ATP5J2-PTCD1** (a locus that represents naturally occurring read-through transcription between the ATP5J2 (ATP synthase, H<sup>+</sup> transporting, mitochondrial Fo complex, subunit F2) and **PTCD1** (pentatricopeptide

repeat domain 1) genes on chromosome 7), **GPR4** (G Protein-Coupled Receptor 4; in the brain may mediate central respiratory sensitivity to CO<sub>2</sub> H<sup>+</sup>), **PNMT** (a **pentalenolactone synthase**; cerebral disease and intellectual disability, hypotonia and mitochondrial disease), **PRDM12** (PR domain zinc finger protein 12; inflammation or degeneration of the sensory nerves), **ITGA5** (Integrin Subunit Alpha 5; paraneoplastic neurologic syndrome), **MEGF6** (Multiple EGF Like Domains 6 intracranial hemorrhage), **LAMA5** (Laminin Subunit Alpha 5; cerebral diseases of vascular origin with epilepsy), **MAP3K6** (Mitogen-Activated Protein Kinase 6, musculoskeletal or connective tissue disease genetic), **IL15RA** (Interleukin 15 Receptor Subunit Alpha; brain inflammatory disease), **RASIP1** (Ras Interacting Protein 1; juvenile primary lateral sclerosis (JPLS), a very rare motor neuron disease characterized by progressive upper motor neuron dysfunction leading to loss of the ability to walk; mitochondrial oxidative phosphorylation disorder with no known mechanism).

The genes upregulated in female corresponded to **OPTN** (Optineurin; amyotrophic lateral sclerosis, a degenerative disorder affecting upper motor neurons in the brain), **UBA6** (Ubiquitin Like Modifier Activating Enzyme 6; developmental and epileptic encephalopathy), **BZW1** (Basic Leucine Zipper And W2 Domains 1; rolandic epilepsy - speech dyspraxia; intellectual disability), and **TMX2** (Thioredoxin Related Transmembrane Protein 2; regulates mitochondrial activity; abnormality in the process of thought including the ability to process information; cognitive, abilities or memory anomaly, in general intellectual disability).

The results for all significant genes from all meta-analyses are further detailed in **Supplementary Table S2**, including adjusted p-value, the log fold change (logFC), and its 95% confidence interval (CI), and the standard error (SE) of the logFC.

**Table 4.** Global meta-analysis results. Expression data for all 7 studies were integrated from the three major brain regions: frontal cortex, striatum tissue and substantia nigra. Significant genes are specified by sex. Genes with a documented association with PD in OpenTargets database (OT) are highlighted in bold type.

Over-expressed in	Significant genes
Males	<b>AC073283.7, ATP5J2-PTCD1, GPR4, IL15RA, ITGA5, LAMA5, MAP3K6, MEGF6, PNMT, PRDM12, RASIP1</b>
Females	<b>BZW1, OPTN, TMX2, UBA6</b>

#### 2.4. Sex-based functional signature in substantia nigra


Our study of sex differences in PD and specifically in the meta-analysis of SN found a total of 237 significant genes differentially expressed (Table 3): 75 more expressed in male than female and 162 genes more expressed in female when comparing with male. Among them, 60 genes (16 up in male and 44 up in female) show an described association with PD, in Open Targets database. The elevated number of genes differentially expressed and involved in sex differences related to PD in SN, led us to focus on this brain region and performed a multiple functional enrichment strategy based on the DGEs of the SN meta-analysis. These complementary approaches provided results that allow for an understanding of sex-differential mechanisms:

##### 2.4.1. Over-Representation Analysis (ORA)

ORA by ClusterProfiler only based on significant genes, revealed that in males the enriched biological functions were related to oxidative stress, such as: detoxification of copper ion, stress response to copper ion, detoxification of inorganic compound, stress response to metal ion, cellular



response to zinc ion, cellular response to copper ion. In females, the ORA overrepresented functions could be summarized up in relation to antigen processing and presentation, pH regulation, proton transmembrane transport, mitochondrial functions and autophagy, cytoskeleton and microtubule transport. These functions contribute to the creation of a neurodegenerative microenvironment which ultimately results in neuronal death. Finally, purine metabolism and ribose metabolism also appeared enriched in females.



**Figure 4.** Summary dot plot of GO Biological Processes meta-analysis results. Only those significant functions with a highest differential effect are shown (top 16 functions in females by adjusted p-value and the only 6 significant functions in males).

#### 2.4.2. Protein-Protein Interaction Analysis

Protein-protein interaction (PPI) networks were calculated from each subset of differentially expressed genes in the substantia nigra meta-analysis using the STRING web tool [34]. The PPI network generated for the 75 overexpressed genes in males showed significantly more edges than expected (p-value 3.87e-05) (Figure 5a) Among all PPIs detected in the analysis, we would like to stand out in men the following clusters of proteins:


**Angiogenesis cluster** (in red): **HSPG2-CSPG4, ITGA5, LAMA5, ENG, PDGFRG, APOC2, APOL1** and **IGFBP7**, this central cluster of highly connected proteins involved in angiogenesis processes.

**Metallothioneins cluster** (in pearl): **MT2A, MT1E, MT1M** are linked to the interferon induced transmembrane proteins **IFITM2, IFITM3** through **HLA-E**.

**Rab13, MICALL12 cluster** (in purple), **MICAL-** like protein 2 Ras-related protein Rab is an effector of small Rab GTPs as Rab13.

**ARPC1B cluster** (in blue), an actin-related protein complex 1B.

**STOM, TMBIM1, CYBA cluster** (in green), with a role in redox homeostasis, response to oxidative stress, inflammation and blood vessel remodeling.



**Figure 5.** Protein-protein interaction (PPI) networks calculated from significant genes in SN meta-analysis. Only network edges with an interaction score greater than 0.7 are represented. a) PPI network generated from over-expressed genes in males (link). b) PPI network generated from over-expressed genes in females (link).

Attending the set of 162 overexpressed genes in females, the PPI network generated showed again significantly more edges than expected ( $p$ -value  $< 1.0e-16$ ) (figure 5b). We found several clusters that were in correlation with upregulated genes in females:

**Microtubule and transport cluster** (in green): this cluster include several proteins related to microtubule reorganization and transport (tubulins alpha: TUBA1B, TUBA3C and beta TUBB4B, Myosin and actin)

**Mitochondria function and metabolism cluster** (in yellow) with proteins as GOT1 and GOT2 (glutamic metabolism), VDAC2 and 3, voltage-dependent anion-selective channel proteins involved in mitochondrial outer membrane permeabilization, negative regulation of intrinsic apoptotic signaling pathway, negative regulation of protein polymerization among other functions. Mitochondrial dysfunction and oxidation are main causes of PD.

**V-ATPase cluster** (in blue) formed by several V-ATPases subunits importantly involved in neuronal diseases.

**Secretogranin cluster** (in blue) that as we showed before members of this family are altered in PD.


**Protein folding, recycling and degradation** (in red) formed by proteasome subunits PSMB5, PSMB7; Ubiquitin UBB, Ubiquitin-protein hidrolase protein UCHL1, Chaperone HSPA8, clathrin and adaptins (E-L system).

#### 2.4.3. Transcription Factors Activity

From the 217 Transcription Factors (TFs) evaluated in viper analysis, we found 40 TFs differentially active (adjusted  $p$ -value  $< 0.05$ ), 29 upregulated in males and 11 upregulated in females (**Figure 6 & Supplementary table S4**).

Among the 29 TFs up-regulated in males such as **ADNP, JUN, MBD3, PRDM14, ESR1, SP1, SMAD3, BATF, CEBPA, ETS1, KLF6, LYL1, NFKB1, RELA, SOX13, SP3, SPI1, STAT1, STAT2, STAT3** to name a few, we would like to highlight that many of them are directly associated to neurodegenerative diseases as Alzheimer or other types of dysfunctions affecting the brain as mental retardation, schizophrenia and autism. Additionally, some of these TFs also appear importantly

involved in immune and neuroinflammatory functions (Supplementary table S4).



**Figure 6.** Activation of significant (adjusted p-value < 0.05) transcription factors coloured by direction of the up-regulation. Yellow indicates a higher activity of the TF in males compared to females. Purple indicates a higher activity of the TF in females compared to males. Activation values are given as Normalized Enrichment Score (NES).

Concerning the TFs up-regulated in females, some have been previously associated with neurodegenerative diseases or cognitive disabilities, such as **ATF3**, **BCL6**, or **PCGF2**. Other TFs upregulated in females could be involved in processes related to neuroinflammation such as **ZBTB7A**, **ZC3H8**, or **NME2**. These TFs play a role in multiple processes, including the immune response, modulating hemopoiesis and regulating the differentiation and activation of T and B lymphocytes, specifically (Supplementary table S4).

The remaining significant TFs, **GTF2B**, **HOXB13**, **MNT**, **ZHX1**, **ZHX2** (in females), and **ETS2**, **KLF5**, **KLF9**, **MAZ**, **MYNN**, **TEAD2**, **ZNF92**, **ZNF175**, **ZNF207** (in males) are poorly characterized or have not been studied in the context of PD. TFs represent a potential source of biomarkers since they can be detected in biological fluids in humans and can indicate the risk for PD [35].

## 2.5. Metafun-PD Web Tool

The Metafun-PD web tool (<http://bioinfo.cipf.es/metafun-pd>) contains information related to the seven studies and 267 samples involved in this study. For each study, this resource includes fold-changes of genes and LOR of functions and pathways that users can explore to identify profiles of interest.

We carried out a total of 4 meta-analyses. For each of the significant genes, Metafun-PD depicts the global activation level for all studies and each study's specific contribution using statistical indicators (LOR, CI, and p-value) and graphical representations by gene as forest and funnel plots. This open resource hopes to contribute to data sharing between researchers, the elaboration of innovative studies, and the discovery of new findings.

Here, we also highlight the importance of including/reporting sex-related data in the results of clinical studies given their general importance in the progression, the severity, and other outcomes in Parkinson disease, as well as in other neurodegenerative disorders. The integration of sex-based differences in this manner has the potential to significantly impact the neurodegenerative biology field.

### 3. Discussion

**Meta-analysis of transcriptomics profiles. PD differs in men and women, to understand such sex-related differences in PD,** we have carry out an individual gene expression meta-analysis in FC, ST and SN regions and a final meta-analysis that integrates studies from all regions. No differential gene expression was detected in FC but MED31 gene was identified in ST, this gene is a mediator of RNA polymerase II transcription subunit 31. Functions associated with this gene are the regulation of lipid metabolism by peroxisome proliferator-activated receptor alpha (PPARalpha) and gene expression [36], [37]. Lipid metabolism dysregulation is key in the accumulation of  $\alpha$ -synuclein ( $\alpha$ -syn) and the formation of Lewy bodies in the brainstem, limbic system, and cortical areas [38]. Cellular stress and inflammatory responses could be induced in the brain by long-chain fatty acids, ceramides, and lipopolysaccharides [39]. MED31 has been associated with neural diseases as Amyotrophic Lateral Sclerosis 3 and Amyotrophic Lateral Sclerosis Type 5 where motor neurons are affected [40] but until now never with PD.

In SN, 237 genes appeared differentially expressed (162 up in females and 75 in males), pointing out that SN is the most affected brain area by PD as it is well known [41]. In males, the genes upregulated in SN can be clustered in:

- **Metallothioneins** family that included genes such as: MT2A, MT1E, MT1M. Metallothioneins (MTs) are small cysteine-rich proteins that play important roles in metal homeostasis and protection against heavy metal toxicity, DNA damage, and oxidative stress. It is documented that metallothionein expression is regulated in response to oxidative stress and inflammation, hallmarks in neurodegenerative diseases, and described as potential markers of neurologic disease processes and treatment response in lysosomal storage disorders (LSDs) [42]. Moreover a strong increase in the expression of metallothioneins has been described in substantia nigra and frontal cortex associated with PD [43].
- **Apolipoproteins** APOL1, APOC2. They are involved in binding lipids to form lipoproteins, whose main function is to transport lipids. Other lipoproteins such as ApoE have been related to aging and neurodegenerative diseases [44], [45]. Lipid metabolism is importantly involved in neurotrophic disorders and correlated with symptoms in PD patients [46].
- **Interferon induced transmembrane proteins** IFITM2, IFITM3, involved in innate immunity modulation, have already been related to other neurodegenerative diseases. In Alzheimer disease (AD), the expression of IFITM3 is induced in neurons and astrocytes by inflammatory cytokines and IFITM3 binds to  $\gamma$ -secretase and upregulates its activity, thereby increasing the production of amyloid- $\beta$  [47], [48].

The final scenario in males targets hallmarks of neurodegeneration as oxidative stress, inflammation and innate immune response.

In case of females, the elevated number of genes dysregulated in SN could be clustered in:

- **Secretogranins family** SCG2, SCG3, SCG5, CHGB. Members of this family are known to

control delivery of peptides and neurotransmitters. Alterations in the granin family have been associated with PD [49].

- **V-ATPase subunits** ATP5B, ATP6AP1, ATP6V0D, ATP6V1B2, ATP6V1E1, ATP6V1G2. Dysfunction of V-ATPase affects lysosomal acidification, which disrupts the clearance of substrates and leads to many disorders, including neurodegenerative diseases [50], [51].
- **TIM22 complex subunits** TIMM8B, TIMM10B, a complex involved in mitochondrial protein import. Alterations in other TIM complexes as TIM23 has been suggested as relevant mechanisms in neurodegenerative diseases [52].
- The meta-analysis highlighted alterations in several groups of proteins with key roles in axonal transport and cytoskeleton stability: **Dyneins family** DYNC1LI1, DYNC1I1, DYNLL1; **Dynactin subunits** DCTN3, DCTN6, ACTR10; and **Actin related proteins family** ACTR3B, ACTR10 and **Tubulin subunits** TUBA1B, TUBA3C, TUBB4B. Alterations in dynein/dynactin complex are responsible of disruption of axonal transport, accumulation of misfolded proteins and motor neuron diseases and described in disorders as amyotrophic lateral sclerosis (ALS) and other neurodegenerative processes so as actin related proteins and tubulin subunits [53]–[55].
- **Mitochondrial porins** VDAC2, VDAC3 are responsible for voltage-dependent anion channels and mitochondrial dysfunction contributing to neurodegenerative diseases [56].
- **Glutamic-oxaloacetic transaminase** cytoplasmic and mitochondrial forms GO1, GOT2. Metabolic processes also can contribute to PD progression [57]. Glutamate metabolism is importantly involved in excitotoxicity and neuron death [58].
- **Serine/Threonine Phosphatase** subunits PPP3CB, PPP2CA .PPP3CB is a Calcium-dependent calmodulin-stimulated protein phosphatase, which plays an essential role in the transduction of intracellular  $Ca^{2+}$ -mediated signals [59], [60]. This protein is related to biological processes such as: axon extension, learning, locomotion, lymphangiogenesis, memory, regulation of synaptic plasticity and synaptic vesicle endocytosis, cytokine and T cell responses. Regarding PPP2CA, is the major phosphatase for microtubule-associated proteins (MAPs) and some of their actions affect to GABA receptor binding, tau protein binding, regulation of apoptotic process and microtubule binding as indicated in UniProtKB [61].

Keeping in mind all the protein families altered in females and their role in biological processes (acidification, microtubule stability, mitochondrial and lysosomal dysfunction, glutamic metabolism, neurotoxicity), highlight their important contribution to the neurodegeneration process and neuronal death that take place in PD. Highlight the important impact in PD of mitochondrial and lysosomal dysfunction, both mitochondrial and lysosomes play a vital role in cellular redox homeostasis. Mitochondrias are vital organelles with multiple functions and their damage can promote a decline in energy production, generation of reactive oxygen species and induction of stress-induced apoptosis. While lysosomes are involved in turnover and degradation of organelles and proteins, those in PD could be mitochondrias and alpha-synuclein aggregates, respectively [62]–[64].

Note that, in males and in females PD patients, the functional profiles inferred seem to be similar: stress oxidative, inflammation and neurodegeneration. However, as we showed, the cluster of proteins defined by the DGEs and the underlying mechanism were different. While in males prevails an environment related to metal homeostasis, lipid metabolism and immunity, in females governs an environment more related to mitochondrial and lysosomal dysfunction, cytoskeletal proteins and glutamic metabolism. These data have important connotations to develop tailored interventions and understand the different requirements of males and females with PD.

Regarding the global meta-analysis, in males 11 genes appeared upregulated in the global meta-analysis (AC073283.7, ATP5J2-PTCD1, GPR4, IL15RA, ITGA5, LAMA5, MAP3K6, MEGF6, PNTM, PRDM12, RASIP1). The majority on these genes are involved in oxidative stress, inflammation, cerebral disorders [65], [66] and associated to neural and intellectual disability and one gene in mitochondrial dysfunction [25] but not described until now in PD bia sex. In females, 4 genes were over expressed (OPTN, UBA6, BZW1, TMX2) related to apoptosis, ubiquitination, and mitochondrial activity. It's described that **Optineurin** (OPTN) interacts with adenovirus E3-14.7K protein and through tumor necrosis factor-alpha or Fas-ligand pathways mediate apoptosis, inflammation or vasoconstriction. Several viruses have been related to etiology of neural diseases although the mechanisms underlying are unknown [67]–[69]. Ubiquitin dysregulation can affect normal PINK1 and Parkin functions that govern mitochondrial quality control and mitophagy process [70]. Newly in women the alteration of these genes results in mitochondrial dysfunction, stress condition, energy depletion and necrotic cell death [71]–[74]. Note that, in both males and females, the final result is practically the same: mitochondrial dysfunction, oxidative stress, inflammation, which ultimately translates into neuronal death, cognitive and intellectual disorders but the genes involved are different. It is the first time that these genes are related to PD taking account sex differences and becoming in candidates for deeper studies...

Highlight that many of the genes identified in the meta-analysis carried out in both, SN and global tissues, have been described in OT to be related to other neural, intellectual and cognitive disorders, and some of them also related to PD, giving confidence to the meta-analysis performed in the present study. Further exploration of these genes in PD may open new perspectives for biomarkers, diagnosis and therapeutics approaches.

### **Sex-based functional profiling**

Based on DGEs analysis in SN, we performed an Over Representation Analysis (ORA), a Protein-Protein Interaction (PPI) network and transcription factors activity estimation (Viper) to get different perspectives of the functional scenario.

#### **ORA**

The ORA showed that DGEs in males were over enriched in functions as detoxification and stress response of several ions. Metal ions can be found in the protein aggregates in PD [75]. Oxidative stress plays an important role in the degeneration of dopaminergic neurons in PD and disruptions in the physiologic maintenance of the redox potential in neurons interfere with several biological processes, ultimately leading to cell death [76]. In females the overexpressed functions correspond to microtubule and cytoskeletal transport, mitochondrial transport along microtubule, macroautophagy, and mainly in antigen processing and presentation (several functions related to antigen processing and presentation appeared overrepresented in females). The  $\alpha$ -syn is a primary trigger of the immune response in PD) [77]. Several studies provide evidence that  $\alpha$ -syn may activate the innate and adaptive immune system, since the degree of microglial activation is directly correlated with  $\alpha$ -syn load in post-mortem brains [77]. Regarding purine metabolism also enriched in women, it is described that urate and other purines correlates with PD severity [78]. Purine-ribose dysregulation has been related to microglia activation (neuroinflammation) and neurodegeneration [9]. These results could suggest a different design of therapeutic strategies in females and males.

#### **PPIs**

PPIs have shown that **angiogenesis , metallothioneins, rab13/MICALL12 , ARPC1B , STOM/ TMBIM1/CYBA , were the most prominent protein interaction clusters in men.** Precisely, angiogenesis occurrence has been described in SN post-mortem tissues from PD patients [79]. While the metallothioneins are documented to be part of the Interferon-Stimulated Genes (ISGs) set [80], [81]. Microglia genes are regulated by Interferon gamma and the ISGs pathway appears upregulated

in other neurodegenerative diseases as Multiple system atrophy [82], [83]. The MICAL-like protein 2 Ras-related protein Rab is an effector of small Rab GTPs as Rab13. Rab13 has been associated to modulate alpha Synuclein aggregation, toxicity and levels [84]. On the other hand, **ARPC1B cluster** seem to be involved in cytolytic activity of CD8 cytotoxic T lymphocytes [85] **and interactions among STOM/TMBIM1/CYBA proteins** were related to redox homeostasis, response to oxidative stress and inflammation and blood vessel remodeling [61], [86]. In case of females PPI included: **microtubule and transport, mitochondria function and metabolism, V-ATPase, secretogranin, protein folding, recycling and degradation clusters**. VDAC2 and 3, voltage-dependent anion-selective channel proteins are importantly involved in mitochondrial outer membrane permeabilization, negative regulation of intrinsic apoptotic signaling pathway and negative regulation of protein polymerization among other functions [61]. As we have already commented mitochondrial dysfunction and oxidation are main causes of PD. And not least the glutamate metabolism of vital importance for neuronal excitability [87]. Moreover, V-ATPases subunits, ATP-dependent proton pumps present in both intracellular compartments and the plasma membrane, are importantly involved in neuronal diseases. These proton pumps have important connotations in defective lysosomal acidification and contribute to virtually all lysosomal storage disorders (LSDs) and to common neurodegenerative diseases like Alzheimer's and Parkinson's [51]. Several members of **secretogranin** are altered in PD [49]. **Finally, protein folding, recycling and degradation** could be key in misfolding and aggregation of toxic alpha-synuclein. Point that PPIs were in correlation with observed in ORA results. Sex-related differences in inflammation, mitochondrial dysfunction and oxidative stress mechanisms have been documented in several studies [14], [18], [20], [21] supporting our results. Importantly, we have shown that the protein nets involved in these mechanisms are different for males and females and could be key to design therapeutic strategies.

#### **TFs**

As we have previously described, a high number of genes, pathways and functions appear dysregulated in PD sex-related. The TFs represent key modulators of gene expression and pathways able to respond to different stimuli including oxidative stress, microglia activation, chronic inflammation, exposure to neurotoxins, and DNA damage [88]. Additionally, TFs are known to be involved in PD pathogenesis and as with other cells, the development, maintenance and survival of neurons depend on the precise control of gene expression by TFs [89]. In males, several TFs appeared upregulated: **ADNP, JUN, MBD3, PRDM14, ESR1**. In OpenTargets database [25], **ADNP** has been associated with phenotypes as "ADNP-related multiple congenital anomalies-intellectual disability-autism spectrum disorder", "Intellectual disability", "mental retardation" or "autism", **JUN** with "Alzheimer's disease" and **PRDM14** with "schizophrenia", while **MBD3** has been related to "Neuropathy, Hereditary Sensory, Type Ie." in GeneCards database [40], being an important TF for neurodevelopment [90], [91]. It has been described that **ESR1** has some polymorphisms that may contribute to an increased PD susceptibility. Men also showed upregulated **SP1**, which seems to regulate the expression of **LRRK2** [92], a protein that is one of the contributing factors to PD pathogenesis. Besides, it has been proposed that inhibition of **SP1** would have beneficial effects in PD models [93]. **SMAD3** also plays an important role in PD and it has been shown that deficiencies in this protein significantly reduce neurogenesis. In addition, **SMAD3** has been associated with several features of PD and dysfunctions of this protein leads to formation of  $\alpha$ -synuclein aggregates or the reduction of dopaminergic axons and dendrites, among others [94]. Several of the upregulated TFs in males (**BATF, CEBPA, ETS1, KLF6, LYL1, NFKB1, RELA, SOX13, SP3, SPI1, STAT1, STAT2, STAT3**), may be involved in neuroinflammatory processes and regulate different functions of the immune response. Concerning the TFs up-regulated in females, some have been previously associated with neurodegenerative diseases or cognitive disabilities, such as **ATF3, BCL6, or PCGF2**. The upregulation of **ATF3** as a consequence of neurological damage and ROS production has been demonstrated in a PD model [95]. **BCL6** is a transcriptional repressor, which has the **ITM2B** gene as a target [96]. **ITM2B** is an important gene in some neurodegenerative diseases such as AD. The **ITM2B** protein binds amyloid precursor protein (APP) and inhibits its processing, reducing the secretion and

accumulation of beta amyloid peptides. **PCGF2** is associated with phenotypes such as "intellectual disability", "global developmental delay" and "mental retardation" as described in OpenTargets database [25]. On the other hand, other TFs could be involved in processes related to neuroinflammation such as **ZBTB7A**, **ZC3H8**, or **NME2**. These TFs play a role in multiple processes, including the immune response, modulating hemopoiesis and regulating the differentiation and activation of T and B lymphocytes, specifically (Supplementary table S4). Biomarkers to detect the degeneration of neurons in the preclinical phase is an urgent need that TFs could supply, although deeper and validation studies must be done.

Finally, we have designed a Metafun-PD web tool (<http://bioinfo.cipf.es/metafun-pd>) to share data that can help and guide other researchers. In this web it is possible to access the information (fold-changes of genes and LOR of functions and pathways ) of the seven studies and 267 samples included in this study. We believe that this kind of tool is needed to facilitate the advance of the scientific community.

**Strengths and limitations.** Sex differences influence the incidence of progression, symptoms, response to treatment and mortality in many diseases, including PD. But the segregation of data by sex does not always occur in research studies, not even in those carried out with the objective of knowing factors for the diagnosis or prognosis of the disease. In our systematic revision many of the studies and data that were excluded because the absence of sex information. We highlight the need of including sex information in research studies and databases because they can have special relevance in health.

Here we have performed an *in silico* approach about sex differences in PD. *In silico* approaches through computational models constitute a potent tool to evaluate and integrate data and results obtained show both: more consensus information and statistical power. In this kind of approach, the sample size is increased with the studies that integrate the meta-analysis in the designs, therefore the main factors causing potential variations can thus be defined. Additionally, our *in silico* approach on PD diseases with sex perspective has been based on FAIR data (Findable, Accessible, Interoperable, Reusable), the management of FAIR for the advancement of scientific community is key. Importantly, research data must be legally capable of being shared and reused in new research. *In silico* approach with FAIR data can contribute to a better characterization of a physiological or disease state in terms of symptoms, diagnosis, prognosis, incidence, mortality, treatment responses... which can finally be translated to clinical and therapeutics alternatives. This type of *in silico* and integrative approach by sex in PD has been carried out by other authors [97] in which transcriptome data from SN were analyzed by Transcriptome Mapper software (TRAM version 1.2). We use a different computational approach: the limma [98] R package for differential expression analyses and the metafor [ref:] R package for gene expression meta-analysis. Besides, we analyzed the three major brain regions affected by PD not only SN as was performed in [97]. Point, the limma R package, especially, uses linear models for analysing designed experiments and the assessment of differential expression and provides the ability to analyse comparisons between many RNA targets simultaneously in arbitrary complicated designed experiments. Empirical Bayesian methods are used to provide stable results even when the number of arrays is small.

Lastly, the *metafor* R package provides an exhaustive set of tools and utilities for conducting meta-analyses and visualizing their results. Resuming individual differential expression results in a global meta-analysis allows an enlargement of the sample size and, therefore, an increment of the statistical power. Definitely, *this strategy* provides a higher support and solidity of results.

## CONCLUSIONS

It is obvious that PD differs in males and females. Our *in silico* approach sex-based has showed that different mechanisms operate in males and females with PD. The TFs represent potential candidates



as biomarkers to early diagnosis that must be further studied and validated. Researches and studies with sex perspective are need to understand better PD and develop tailored interventions that take into account the distinct requirements of men and women with PD. **Finally, it is essential to share data and use open platforms for scientific advancement.**

## 4. Methods

All bioinformatics and statistical analysis were performed using R software v.3.6.3 [99]. **Supplementary Table S3** details R packages and versions.

### 4.1. Study Search and Selection

Available datasets were collected from GEO [23] and ArrayExpress [24] public repositories. A systematic search of all published studies in public repositories (2002-2020), was conducted between June to September 2020 following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines [33]. The next keywords were employed in the search: “Parkinson”, “Parkinson’s Disease” and “PD”. Search results were restricted to transcriptomics assays on *Homo sapiens*. Cell lines/cultures based studies were discarded. Among these results, studies were selected based on the following inclusion criteria:

- Control and PD affected subjects included
- Sex, disease status, and brain region variables registered
- RNA extracted directly from postmortem brain tissues
- Brain tissues from either cortex, striatum or substantia nigra
- Sample size of > 3 for case and control groups in both sexes

Finally, normalized gene expression data of eight array PD datasets (E-MTAB-1194, E-MEXP-1416, GSE28894, GSE8397, GSE20295, GSE20159, GSE7621, and GSE20146) were retrieved using both R packages *GEOquery* [100] and *ArrayExpress* [101].

### 4.2. Individual Transcriptomics Analysis

Individual transcriptomics analysis was performed on every single selected study. It consisted of two steps: pre-processing and differential expression analysis.

Data pre-processing included the standardization of the nomenclature of the clinical variables included in each study, the homogenization of gene annotation and a data exploratory analysis. We assessed the normalization methods performed by the original authors for each dataset, and  $\log_2$  transformed the data matrices when necessary. All probe sets were annotated to HUGO gene symbols [102] using *Biomart* [103] R package. When dealing with duplicated probe-to-symbol mappings, the median of their expression values was calculated. The exploratory analysis included unsupervised clustering and PCA to detect patterns of expression between samples and genes and the presence of batch effects in each study. At this point, the GSE20159 study was excluded for presenting a strong batch effect with a critical impact on differential expression analysis.

Differential expression analyses were performed using the *limma* [98] R package. To detect differentially expressed genes in male and female Parkinson’s Disease patients, the following contrast was applied:

$$(PD.W - Control.W) - (PD.M - Control.M)$$

where PD.W, Control.W, PD.M and Control.M correspond to PD affected females, control females, PD affected males, and control males, respectively. For every study containing samples from two or more brain tissues, contrasts were applied to: i) each tissue separately ii) whole set of samples. When necessary, batch effect was included as a categorical variable on the *limma* linear model to reduce its impact on data. P-values were calculated and corrected by Benjamini-Hochberg procedure [104]. This comparison allows the detection of genes altered by the disease and that have higher or lower activity in females when compared to males. Significant genes were considered when adjusted p-value < 0.05.

#### 4.3. Gene Expression Meta-Analysis

Differential gene expression results were integrated into four different meta-analyses [105] by brain region: cortex, striatum, substantia nigra and all regions. Meta-analyses were implemented with the R package *metafor* [106].

Meta-analysis was applied under the DerSimonian & Laird random-effects model [107], taking into account individual study heterogeneity. This model considers the variability of individual studies by increasing the weights of studies with less variability when computing meta-analysis results. Thus, the most robust functions between studies are highlighted.

P-values, corrected p-values, log-odds ratios (LOR), and 95% CIs of the LOR were calculated for each evaluated gene. Functions and pathways with corrected p-value < 0.05 were considered significant, and both funnel and forest plots were computed for each. These representations were checked to assess for possible biased results, where LOR represents the effect size of a gene, and the SE of the LOR serves as a study precision measure [108]. Sensitivity analysis (leave-one-out cross-validation) was conducted for each significant gene to verify possible alterations in the results due to the inclusion of any study. The Open Targets platform [25] (release 21.06) was used to test the association of genes to diseases.

#### 4.4. Sex-based functional signature in substantia nigra

Gene Meta-Analysis of substantia nigra studies revealed an important set of differentially expressed genes between males and females. Several analyses were carried out to identify the functional implications of these differences (figure 6).

In the first place, we made use of the Over Representation Analysis (ORA) [109], through the R package *clusterProfiler* [110], to determine the biological functions and pathways over-represented in the following gene sets: i) Up-regulated genes in females ii) Up-regulated genes in males iii) Full set of differentially expressed genes. P-values and corrected p-values were calculated for each GO term, from the three ontologies [111], and for each KEGG pathway [112]. Every function and pathway with a corrected p-value < 0.05 was labelled as over-represented in every concrete gene set.

In the second place, we calculated protein-protein association networks for each subset of genes using the STRING web tool [34]. Total number of edges were examined and protein-protein integration (PPI) enrichment was assessed for each network using the default parameters.


Finally, in order to estimate Transcription Factor activities, we perform a viper [113] analysis with human regulons obtained from *DoRothEA* [114] R package, using the consensus logFC of each gene evaluated in meta-analysis as gene expression signature. We selected regulons with a confidence level of A, B, C, or D, excluding those with less than 25 genes. The p-values were corrected with the Benjamini & Hochberg method.

#### 4.5. Metafun-PD Web Tool

All data and results generated in the different steps of the meta-analysis are available in the Metafun-PD web tool (<http://bioinfo.cipf.es/metafun-pd>), which is freely accessible to any user and allows the confirmation of the results described in this manuscript and the exploration of other results of interest.

The front-end was developed using the Angular Framework. The interactive graphics used in this web resource have been implemented with Plot.ly [115] the exploratory analysis cluster plot has been generated with ggplot2 [116].

This easy-to-use resource is divided into five sections: 1) Summary of analysis results in each phase. Then, for each of the studies, the detailed results of the 2) exploratory analysis and 3) differential expression. 4) Gene Meta-Analysis results of the 4 different performed meta-analyses, The user can interact with the web tool through graphics and tables and search for specific information for a gene or function. Finally, section 5) provides several indicators for the genes and significant functions identified in the meta-analysis that inform whether they are more active in males or females.



**Figure 6.** Workflow and analysis design. All studies were retrieved from GEO-NCBI and ArrayExpress data repositories. After data exploration and preprocessing, differential expression analysis (DEA) was performed on each selected study, getting as many contrasts as brain regions contained and an additional contrast for the whole set of samples. DEA results were combined in four different gene meta-analyses: SN, CT, ST and all regions combined. Finally, several functional profiling methodologies were applied to characterize SN meta-analysis results.

## DATA AVAILABILITY

The data used for the analyses described in this work is publicly available at GEO

(<https://www.ncbi.nlm.nih.gov/geo/>) and ArrayExpress (<https://www.ebi.ac.uk/arrayexpress/>). The accession numbers of the GEO datasets downloaded are: GSE8397, GSE20295, GSE7621, GSE20146 and GSE28894. The accession numbers of the ArrayExpress datasets downloaded are: E-MTAB-1194 and E-MEXP-1416.

### CODE AVAILABILITY

The code developed for the analyses described in this work is publicly available at GitHub ([https://github.com/adlpecer/PD\\_GeneMetaanalysis](https://github.com/adlpecer/PD_GeneMetaanalysis)). All software and versions used are detailed in Supplementary Table S3.

### REFERENCES

- [1] J. Benito-Leon, '[Epidemiology of Parkinson's disease in Spain and its contextualisation in the world]', *Rev. Neurol.*, vol. 66, no. 4, pp. 125–134, Feb. 2018.
- [2] W. Poewe *et al.*, 'Parkinson disease', *Nat. Rev. Dis. Primer*, vol. 3, no. 1, p. 17013, Dec. 2017, doi: 10.1038/nrdp.2017.13.
- [3] J. Heller, I. Dogan, J. B. Schulz, and K. Reetz, 'Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?', *Aging Dis.*, vol. 5, no. 1, pp. 63–75, Feb. 2014, doi: 10.14366/AD.2014.050063.
- [4] H. A. Hanagasi, Z. Tufekcioglu, and M. Emre, 'Dementia in Parkinson's disease', *J. Neurol. Sci.*, vol. 374, pp. 26–31, Mar. 2017, doi: 10.1016/j.jns.2017.01.012.
- [5] J. Leszek, G. E. Barreto, K. Gąsiorowski, E. Koutsouraki, M. Ávila-Rodrigues, and G. Aliev, 'Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System', *CNS Neurol. Disord. Drug Targets*, vol. 15, no. 3, pp. 329–336, 2016, doi: 10.2174/1871527315666160202125914.
- [6] R. Cabezas *et al.*, 'Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease', *Front. Cell. Neurosci.*, vol. 8, Aug. 2014, doi: 10.3389/fncel.2014.00211.
- [7] J. Fukae, Y. Mizuno, and N. Hattori, 'Mitochondrial dysfunction in Parkinson's disease', *Mitochondrion*, vol. 7, no. 1–2, pp. 58–62, Feb. 2007, doi: 10.1016/j.mito.2006.12.002.
- [8] R. Lee Mosley *et al.*, 'Neuroinflammation, oxidative stress, and the pathogenesis of Parkinson's disease', *Clin. Neurosci. Res.*, vol. 6, no. 5, pp. 261–281, Dec. 2006, doi: 10.1016/j.cnr.2006.09.006.
- [9] M. Misiak, C. Beyer, and S. Arnold, 'Gender-specific role of mitochondria in the vulnerability of 6-hydroxydopamine-treated mesencephalic neurons', *Biochim. Biophys. Acta BBA - Bioenerg.*, vol. 1797, no. 6–7, pp. 1178–1188, Jun. 2010, doi: 10.1016/j.bbabi.2010.04.009.
- [10] O.-B. Tysnes and A. Storstein, 'Epidemiology of Parkinson's disease', *J. Neural Transm. Vienna Austria 1996*, vol. 124, no. 8, pp. 901–905, Aug. 2017, doi: 10.1007/s00702-017-1686-y.
- [11] M. Picillo, A. Nicoletti, V. Fetoni, B. Garavaglia, P. Barone, and M. T. Pellecchia, 'The relevance of gender in Parkinson's disease: a review', *J. Neurol.*, vol. 264, no. 8, pp. 1583–1607, Aug. 2017, doi: 10.1007/s00415-016-8384-9.
- [12] L. Hirsch, N. Jette, A. Frolkis, T. Steeves, and T. Pringsheim, 'The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis', *Neuroepidemiology*, vol. 46, no. 4, pp. 292–300, 2016, doi: 10.1159/000445751.
- [13] N. Dahodwala, Q. Pei, and P. Schmidt, 'Sex Differences in the Clinical Progression of Parkinson's Disease', *J. Obstet. Gynecol. Neonatal Nurs.*, vol. 45, no. 5, pp. 749–756, Sep. 2016, doi: 10.1016/j.jogn.2016.05.002.
- [14] D. Colombo *et al.*, 'The "Gender Factor" in Wearing-Off among Patients with Parkinson's Disease: A Post Hoc Analysis of DEEP Study', *Sci. World J.*, vol. 2015, pp. 1–10, 2015, doi: 10.1155/2015/787451.
- [15] K. A. Bjørnara, E. Dietrichs, and M. Toft, 'REM sleep behavior disorder in Parkinson's disease – Is there a gender difference?', *Parkinsonism Relat. Disord.*, vol. 19, no. 1, pp. 120–122, Jan. 2013,

- doi: 10.1016/j.parkreldis.2012.05.027.
- [16] E. Betancourt, J. Wachtel, M. Michaelos, M. Haggerty, J. Conforti, and M. F. Kritzer, 'The impact of biological sex and sex hormones on cognition in a rat model of early, pre-motor Parkinson's disease', *Neuroscience*, vol. 345, pp. 297–314, Mar. 2017, doi: 10.1016/j.neuroscience.2016.05.041.
- [17] P. Martinez-Martin, C. Rodriguez-Blazquez, M. M. Kurtis, K. R. Chaudhuri, and on Behalf of the NMSS Validation Group, 'The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease: Nms and HRQ O L in Parkinson's Disease', *Mov. Disord.*, vol. 26, no. 3, pp. 399–406, Feb. 2011, doi: 10.1002/mds.23462.
- [18] C. A. Haaxma *et al.*, 'Gender differences in Parkinson's disease', *J. Neurol. Neurosurg. Amp Psychiatry*, vol. 78, no. 8, pp. 819–824, Aug. 2007, doi: 10.1136/jnnp.2006.103788.
- [19] G. E. Gillies, I. S. Pienaar, S. Vohra, and Z. Qamhawi, 'Sex differences in Parkinson's disease', *Front. Neuroendocrinol.*, vol. 35, no. 3, pp. 370–384, Aug. 2014, doi: 10.1016/j.yfrne.2014.02.002.
- [20] H. Loke, V. Harley, and J. Lee, 'Biological factors underlying sex differences in neurological disorders', *Int. J. Biochem. Cell Biol.*, vol. 65, pp. 139–150, Aug. 2015, doi: 10.1016/j.biocel.2015.05.024.
- [21] S. Mitra *et al.*, 'Gender-specific brain regional variation of neurons, endogenous estrogen, neuroinflammation and glial cells during rotenone-induced mouse model of Parkinson's disease', *Neuroscience*, vol. 292, pp. 46–70, Apr. 2015, doi: 10.1016/j.neuroscience.2014.12.052.
- [22] F. Shephard, O. Greville-Heygate, S. Liddell, R. Emes, and L. Chakrabarti, 'Analysis of Mitochondrial haemoglobin in Parkinson's disease brain', *Mitochondrion*, vol. 29, pp. 45–52, Jul. 2016, doi: 10.1016/j.mito.2016.05.001.
- [23] T. Barrett *et al.*, 'NCBI GEO: archive for functional genomics data sets—update', *Nucleic Acids Res.*, vol. 41, no. D1, pp. D991–D995, Nov. 2012, doi: 10.1093/nar/gks1193.
- [24] A. Athar *et al.*, 'ArrayExpress update - from bulk to single-cell expression data', *Nucleic Acids Res.*, vol. 47, no. D1, pp. D711–D715, Jan. 2019, doi: 10.1093/nar/gky964.
- [25] D. Ochoa *et al.*, 'Open Targets Platform: supporting systematic drug–target identification and prioritisation', *Nucleic Acids Res.*, vol. 49, no. D1, pp. D1302–D1310, Jan. 2021, doi: 10.1093/nar/gkaa1027.
- [26] P. Garcia-Esparcia *et al.*, 'Functional genomics reveals dysregulation of cortical olfactory receptors in Parkinson disease: novel putative chemoreceptors in the human brain', *J. Neuropathol. Exp. Neurol.*, vol. 72, no. 6, pp. 524–539, Jun. 2013, doi: 10.1097/NEN.0b013e318294fd76.
- [27] I. Cantuti-Castelvetri *et al.*, 'Effects of gender on nigral gene expression and parkinson disease', *Neurobiol. Dis.*, vol. 26, no. 3, pp. 606–614, Jun. 2007, doi: 10.1016/j.nbd.2007.02.009.
- [28] L. B. Moran, D. C. Duke, M. Deprez, D. T. Dexter, R. K. B. Pearce, and M. B. Graeber, 'Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease', *Neurogenetics*, vol. 7, no. 1, pp. 1–11, Mar. 2006, doi: 10.1007/s10048-005-0020-2.
- [29] D. C. Duke, L. B. Moran, R. K. B. Pearce, and M. B. Graeber, 'The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability', *Neurogenetics*, vol. 8, no. 2, pp. 83–94, Apr. 2007, doi: 10.1007/s10048-006-0077-6.
- [30] Y. Zhang, M. James, F. A. Middleton, and R. L. Davis, 'Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms', *Am. J. Med. Genet. Part B Neuropsychiatr. Genet. Off. Publ. Int. Soc. Psychiatr. Genet.*, vol. 137B, no. 1, pp. 5–16, Aug. 2005, doi: 10.1002/ajmg.b.30195.
- [31] B. Zheng *et al.*, 'PGC-1 $\alpha$ , a potential therapeutic target for early intervention in Parkinson's disease', *Sci. Transl. Med.*, vol. 2, no. 52, p. 52ra73, Oct. 2010, doi: 10.1126/scitranslmed.3001059.
- [32] T. G. Lesnick *et al.*, 'A genomic pathway approach to a complex disease: axon guidance and Parkinson disease', *PLoS Genet.*, vol. 3, no. 6, p. e98, Jun. 2007, doi: 10.1371/journal.pgen.0030098.

- [33] D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, 'Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement', *PLoS Med.*, vol. 6, no. 7, p. e1000097, Jul. 2009, doi: 10.1371/journal.pmed.1000097.
- [34] D. Szklarczyk *et al.*, 'STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets', *Nucleic Acids Res.*, vol. 47, no. D1, pp. D607–D613, Jan. 2019, doi: 10.1093/nar/gky1131.
- [35] M. Eller and D. R. Williams, 'Biological fluid biomarkers in neurodegenerative parkinsonism', *Nat. Rev. Neurol.*, vol. 5, no. 10, pp. 561–570, Oct. 2009, doi: 10.1038/nrneuro.2009.135.
- [36] E. P. Beadle, J. A. Straub, B. A. Bunnell, and J. J. Newman, 'MED31 involved in regulating self-renewal and adipogenesis of human mesenchymal stem cells', *Mol. Biol. Rep.*, vol. 45, no. 5, pp. 1545–1550, Oct. 2018, doi: 10.1007/s11033-018-4241-5.
- [37] M. Schneider *et al.*, 'The Nuclear Pore-Associated TREX-2 Complex Employs Mediator to Regulate Gene Expression', *Cell*, vol. 162, no. 5, pp. 1016–1028, Aug. 2015, doi: 10.1016/j.cell.2015.07.059.
- [38] I. Alecu and S. A. L. Bennett, 'Dysregulated Lipid Metabolism and Its Role in  $\alpha$ -Synucleinopathy in Parkinson's Disease', *Front. Neurosci.*, vol. 13, p. 328, 2019, doi: 10.3389/fnins.2019.00328.
- [39] C. A. Mullins *et al.*, 'Neural Underpinnings of Obesity: The Role of Oxidative Stress and Inflammation in the Brain', *Antioxid. Basel Switz.*, vol. 9, no. 10, p. E1018, Oct. 2020, doi: 10.3390/antiox9101018.
- [40] G. Stelzer *et al.*, 'The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses', *Curr. Protoc. Bioinforma.*, vol. 54, no. 1, Jun. 2016, doi: 10.1002/cpbi.5.
- [41] J. M. Viveros-Paredes, R. E. Gonzalez-Castañeda, A. Escalante-Castañeda, A. R. Tejada-Martínez, F. Castañeda-Achutiguí, and M. E. Flores-Soto, 'Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage', *Neurol. Barc. Spain*, vol. 34, no. 3, pp. 143–152, Apr. 2019, doi: 10.1016/j.nrl.2016.11.008.
- [42] M. Cesani *et al.*, 'Metallothioneins as dynamic markers for brain disease in lysosomal disorders', *Ann. Neurol.*, vol. 75, no. 1, pp. 127–137, Jan. 2014, doi: 10.1002/ana.24053.
- [43] G. J. Michael, S. Esmailzadeh, L. B. Moran, L. Christian, R. K. B. Pearce, and M. B. Graeber, 'Up-regulation of metallothionein gene expression in Parkinsonian astrocytes', *neurogenetics*, vol. 12, no. 4, pp. 295–305, Nov. 2011, doi: 10.1007/s10048-011-0294-5.
- [44] Y. Yin and Z. Wang, 'ApoE and Neurodegenerative Diseases in Aging', in *Aging and Aging-Related Diseases*, vol. 1086, Z. Wang, Ed. Singapore: Springer Singapore, 2018, pp. 77–92. doi: 10.1007/978-981-13-1117-8\_5.
- [45] S. Krasemann *et al.*, 'The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases', *Immunity*, vol. 47, no. 3, pp. 566–581.e9, Sep. 2017, doi: 10.1016/j.immuni.2017.08.008.
- [46] M.-X. Dong, Y.-D. Wei, and L. Hu, 'The disturbance of lipid metabolism is correlated with neuropsychiatric symptoms in patients with Parkinson's disease', *Chem. Phys. Lipids*, vol. 239, p. 105112, Sep. 2021, doi: 10.1016/j.chemphyslip.2021.105112.
- [47] J.-Y. Hur *et al.*, 'The innate immunity protein IFITM3 modulates  $\gamma$ -secretase in Alzheimer's disease', *Nature*, vol. 586, no. 7831, pp. 735–740, Oct. 2020, doi: 10.1038/s41586-020-2681-2.
- [48] A. Y. Yao and R. Yan, 'Activity of Alzheimer's  $\gamma$ -secretase is linked to changes of interferon-induced transmembrane proteins (IFITM) in innate immunity', *Mol. Neurodegener.*, vol. 15, no. 1, p. 69, Dec. 2020, doi: 10.1186/s13024-020-00417-0.
- [49] M. S. Rotunno *et al.*, 'Cerebrospinal fluid proteomics implicates the granin family in Parkinson's disease', *Sci. Rep.*, vol. 10, no. 1, p. 2479, Dec. 2020, doi: 10.1038/s41598-020-59414-4.
- [50] Q. Song, B. Meng, H. Xu, and Z. Mao, 'The emerging roles of vacuolar-type ATPase-dependent Lysosomal acidification in neurodegenerative diseases', *Transl. Neurodegener.*, vol. 9, no. 1, p. 17, Dec. 2020, doi: 10.1186/s40035-020-00196-0.
- [51] M. B. Bagh *et al.*, 'Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in

- a neurodegenerative lysosomal storage disease model', *Nat. Commun.*, vol. 8, no. 1, p. 14612, Apr. 2017, doi: 10.1038/ncomms14612.
- [52] S. Yablonska *et al.*, 'Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23', *Proc. Natl. Acad. Sci.*, vol. 116, no. 33, pp. 16593–16602, Aug. 2019, doi: 10.1073/pnas.1904101116.
- [53] F. Tanaka, M. Waza, M. Yamamoto, and G. Sobue, 'Exploration of pathogenesis and therapy development for ALS employing sporadic disease model', *Rinsho Shinkeigaku*, vol. 49, no. 11, pp. 811–813, 2009, doi: 10.5692/clinicalneuro.49.811.
- [54] F. Tanaka, K. Ikenaka, M. Yamamoto, and G. Sobue, 'Neuropathology and omics in motor neuron diseases: Neuropathology and Omics in MND', *Neuropathology*, vol. 32, no. 4, pp. 458–462, Aug. 2012, doi: 10.1111/j.1440-1789.2011.01281.x.
- [55] J. Eira, C. S. Silva, M. M. Sousa, and M. A. Liz, 'The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders', *Prog. Neurobiol.*, vol. 141, pp. 61–82, Jun. 2016, doi: 10.1016/j.pneurobio.2016.04.007.
- [56] M. Caterino, M. Ruoppolo, A. Mandola, M. Costanzo, S. Orrù, and E. Imperlini, 'Protein–protein interaction networks as a new perspective to evaluate distinct functional roles of voltage-dependent anion channel isoforms', *Mol. Biosyst.*, vol. 13, no. 12, pp. 2466–2476, 2017, doi: 10.1039/C7MB00434F.
- [57] D. Venkatesan, M. Iyer, A. Narayanasamy, K. Siva, and B. Vellingiri, 'Kynurenine pathway in Parkinson's disease—An update', *eNeurologicalSci*, vol. 21, p. 100270, Dec. 2020, doi: 10.1016/j.ensci.2020.100270.
- [58] L. Iovino, M. E. Tremblay, and L. Civiero, 'Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells', *J. Pharmacol. Sci.*, vol. 144, no. 3, pp. 151–164, Nov. 2020, doi: 10.1016/j.jphs.2020.07.011.
- [59] S. Kilka, F. Erdmann, A. Migdoll, G. Fischer, and M. Weiwad, 'The proline-rich N-terminal sequence of calcineurin A $\beta$  determines substrate binding', *Biochemistry*, vol. 48, no. 9, pp. 1900–1910, Mar. 2009, doi: 10.1021/bi8019355.
- [60] S.-J. Li *et al.*, 'Cooperative autoinhibition and multi-level activation mechanisms of calcineurin', *Cell Res.*, vol. 26, no. 3, pp. 336–349, Mar. 2016, doi: 10.1038/cr.2016.14.
- [61] The UniProt Consortium *et al.*, 'UniProt: the universal protein knowledgebase in 2021', *Nucleic Acids Res.*, vol. 49, no. D1, pp. D480–D489, Jan. 2021, doi: 10.1093/nar/gkaa1100.
- [62] A. W. Kao, A. McKay, P. P. Singh, A. Brunet, and E. J. Huang, 'Progranulin, lysosomal regulation and neurodegenerative disease', *Nat. Rev. Neurosci.*, vol. 18, no. 6, pp. 325–333, Jun. 2017, doi: 10.1038/nrn.2017.36.
- [63] U. V. Mahajan *et al.*, 'Dysregulation of multiple metabolic networks related to brain transmethylation and polyamine pathways in Alzheimer disease: A targeted metabolomic and transcriptomic study', *PLoS Med.*, vol. 17, no. 1, p. e1003012, Jan. 2020, doi: 10.1371/journal.pmed.1003012.
- [64] S. W. Ryter, D. Bhatia, and M. E. Choi, 'Autophagy: A Lysosome-Dependent Process with Implications in Cellular Redox Homeostasis and Human Disease', *Antioxid. Redox Signal.*, vol. 30, no. 1, pp. 138–159, Jan. 2019, doi: 10.1089/ars.2018.7518.
- [65] E. M. Rocha, B. De Miranda, and L. H. Sanders, 'Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease', *Neurobiol. Dis.*, vol. 109, no. Pt B, pp. 249–257, Jan. 2018, doi: 10.1016/j.nbd.2017.04.004.
- [66] Y. Xu, J. Shen, and Z. Ran, 'Emerging views of mitophagy in immunity and autoimmune diseases', *Autophagy*, vol. 16, no. 1, pp. 3–17, Jan. 2020, doi: 10.1080/15548627.2019.1603547.
- [67] L. Klingseisen *et al.*, 'E3-14.7K is recruited to TNF-receptor 1 and blocks TNF cytolysis independent from interaction with optineurin', *PLoS One*, vol. 7, no. 6, p. e38348, 2012, doi: 10.1371/journal.pone.0038348.
- [68] L. You *et al.*, 'Enterovirus 71 induces neural cell apoptosis and autophagy through promoting ACOX1 downregulation and ROS generation', *Virulence*, vol. 11, no. 1, pp. 537–553, Dec. 2020,

- doi: 10.1080/21505594.2020.1766790.
- [69] Z. He *et al.*, 'Neural progenitor cell pyroptosis contributes to Zika virus-induced brain atrophy and represents a therapeutic target', *Proc. Natl. Acad. Sci. U. S. A.*, vol. 117, no. 38, pp. 23869–23878, Sep. 2020, doi: 10.1073/pnas.2007773117.
- [70] A. M. Pickrell and R. J. Youle, 'The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease', *Neuron*, vol. 85, no. 2, pp. 257–273, Jan. 2015, doi: 10.1016/j.neuron.2014.12.007.
- [71] N. J. Kramer *et al.*, 'CRISPR–Cas9 screens in human cells and primary neurons identify modifiers of C9ORF72 dipeptide-repeat-protein toxicity', *Nat. Genet.*, vol. 50, no. 4, pp. 603–612, Apr. 2018, doi: 10.1038/s41588-018-0070-7.
- [72] K. Mao *et al.*, 'Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes  $\alpha$ -synuclein degradation via transcription factor EB-dependent autophagy in mutant  $\alpha$ -synucleinA53T model of Parkinson's disease', *Aging Cell*, vol. 19, no. 6, Jun. 2020, doi: 10.1111/acer.13163.
- [73] T. Fishman-Jacob, L. Reznichenko, M. B. H. Youdim, and S. A. Mandel, 'A Sporadic Parkinson Disease Model via Silencing of the Ubiquitin-Proteasome/E3 Ligase Component SKP1A', *J. Biol. Chem.*, vol. 284, no. 47, pp. 32835–32845, Nov. 2009, doi: 10.1074/jbc.M109.034223.
- [74] F. C. Fiesel, E. L. Moussaud-Lamodière, M. Ando, and W. Springer, 'Select E2 enzymes differentially regulate parkin activation and mitophagy', *J. Cell Sci.*, p. jcs.147520, Jan. 2014, doi: 10.1242/jcs.147520.
- [75] R. Moons *et al.*, 'Metal ions shape  $\alpha$ -synuclein', *Sci. Rep.*, vol. 10, no. 1, p. 16293, Oct. 2020, doi: 10.1038/s41598-020-73207-9.
- [76] V. Dias, E. Junn, and M. M. Mouradian, 'The Role of Oxidative Stress in Parkinson's Disease', *J. Park. Dis.*, vol. 3, no. 4, pp. 461–491, 2013, doi: 10.3233/JPD-130230.
- [77] H. E. Allen Reish and D. G. Standaert, 'Role of  $\alpha$ -Synuclein in Inducing Innate and Adaptive Immunity in Parkinson Disease', *J. Park. Dis.*, vol. 5, no. 1, pp. 1–19, 2015, doi: 10.3233/JPD-140491.
- [78] M. Von Seggern, C. Szarowicz, M. Swanson, S. Cavotta, S. T. Pike, and J. T. Lamberts, 'Purine molecules in Parkinson's disease: Analytical techniques and clinical implications', *Neurochem. Int.*, vol. 139, p. 104793, Oct. 2020, doi: 10.1016/j.neuint.2020.104793.
- [79] B. Desai Bradaric, A. Patel, J. A. Schneider, P. M. Carvey, and B. Hendey, 'Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy', *J. Neural Transm.*, vol. 119, no. 1, pp. 59–71, Jan. 2012, doi: 10.1007/s00702-011-0684-8.
- [80] W. M. Schneider, M. D. Chevillotte, and C. M. Rice, 'Interferon-Stimulated Genes: A Complex Web of Host Defenses', *Annu. Rev. Immunol.*, vol. 32, no. 1, pp. 513–545, Mar. 2014, doi: 10.1146/annurev-immunol-032713-120231.
- [81] U. Boehm, T. Klamp, M. Groot, and J. C. Howard, 'CELLULAR RESPONSES TO INTERFERON- $\gamma$ ', *Annu. Rev. Immunol.*, vol. 15, no. 1, pp. 749–795, Apr. 1997, doi: 10.1146/annurev.immunol.15.1.749.
- [82] L. B. Moran, D. C. Duke, and M. B. Graeber, 'The microglial gene regulatory network activated by interferon-gamma', *J. Neuroimmunol.*, vol. 183, no. 1–2, pp. 1–6, Feb. 2007, doi: 10.1016/j.jneuroim.2006.10.023.
- [83] Y. Inoue *et al.*, 'The stimulator of interferon genes (STING) pathway is upregulated in striatal astrocytes of patients with multiple system atrophy', *Neurosci. Lett.*, vol. 757, p. 135972, Jul. 2021, doi: 10.1016/j.neulet.2021.135972.
- [84] S. A. Gonçalves and T. F. Outeiro, 'Traffic jams and the complex role of  $\alpha$ -Synuclein aggregation in Parkinson disease', *Small GTPases*, vol. 8, no. 2, pp. 78–84, Apr. 2017, doi: 10.1080/21541248.2016.1199191.
- [85] L. O. Randzavola *et al.*, 'Loss of ARPC1B impairs cytotoxic T lymphocyte maintenance and cytolytic activity', *J. Clin. Invest.*, vol. 129, no. 12, pp. 5600–5614, Dec. 2019, doi:



- 10.1172/JCI129388.
- [86] F. Gong, J. Gu, and H. Wang, 'Up regulated Tmbim1 activation promotes high fat diet (HFD)-induced cardiomyopathy by enhancement of inflammation and oxidative stress', *Biochem. Biophys. Res. Commun.*, vol. 504, no. 4, pp. 797–804, Oct. 2018, doi: 10.1016/j.bbrc.2018.08.059.
- [87] Z. Zhang *et al.*, 'Roles of Glutamate Receptors in Parkinson's Disease', *Int. J. Mol. Sci.*, vol. 20, no. 18, p. E4391, Sep. 2019, doi: 10.3390/ijms20184391.
- [88] K. Tao *et al.*, 'Salidroside Protects Against 6-Hydroxydopamine-Induced Cytotoxicity by Attenuating ER Stress', *Neurosci. Bull.*, vol. 32, no. 1, pp. 61–69, Feb. 2016, doi: 10.1007/s12264-015-0001-x.
- [89] R. Wang, S. Yang, T. Nie, G. Zhu, D. Feng, and Q. Yang, 'Transcription Factors: Potential Cell Death Markers in Parkinson's Disease', *Neurosci. Bull.*, vol. 33, no. 5, pp. 552–560, Oct. 2017, doi: 10.1007/s12264-017-0168-4.
- [90] E. Knock *et al.*, 'The methyl binding domain 3/nucleosome remodelling and deacetylase complex regulates neural cell fate determination and terminal differentiation in the cerebral cortex', *Neural Develop.*, vol. 10, no. 1, p. 13, Dec. 2015, doi: 10.1186/s13064-015-0040-z.
- [91] A. Hoffmann and D. Spengler, 'Chromatin Remodeling Complex NuRD in Neurodevelopment and Neurodevelopmental Disorders', *Front. Genet.*, vol. 10, p. 682, Jul. 2019, doi: 10.3389/fgene.2019.00682.
- [92] J. Wang and W. Song, 'Regulation of LRRK2 promoter activity and gene expression by Sp1', *Mol. Brain*, vol. 9, no. 1, p. 33, Dec. 2016, doi: 10.1186/s13041-016-0215-5.
- [93] L. Yao *et al.*, 'Inhibition of transcription factor SP1 produces neuroprotective effects through decreasing MAO B activity in MPTP/MPP+ Parkinson's disease models', *J. Neurosci. Res.*, vol. 96, no. 10, pp. 1663–1676, Oct. 2018, doi: 10.1002/jnr.24266.
- [94] M. Muñoz, N. de la Fuente, and A. Sánchez-Capelo, 'TGF- $\beta$ /Smad3 Signalling Modulates GABA Neurotransmission: Implications in Parkinson's Disease', *Int. J. Mol. Sci.*, vol. 21, no. 2, p. 590, Jan. 2020, doi: 10.3390/ijms21020590.
- [95] Q. Zhao *et al.*, 'Echinacoside Protects Against MPP+-Induced Neuronal Apoptosis via ROS/ATF3/CHOP Pathway Regulation', *Neurosci. Bull.*, vol. 32, no. 4, pp. 349–362, Aug. 2016, doi: 10.1007/s12264-016-0047-4.
- [96] B. W. Baron and P. Pytel, 'Expression Pattern of the BCL6 and ITM2B Proteins in Normal Human Brains and in Alzheimer Disease', *Appl. Immunohistochem. Mol. Morphol.*, vol. 25, no. 7, pp. 489–496, Aug. 2017, doi: 10.1097/PAI.0000000000000329.
- [97] E. Mariani *et al.*, 'Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinson's Disease Data', *Genes*, vol. 9, no. 6, p. 275, May 2018, doi: 10.3390/genes9060275.
- [98] M. E. Ritchie *et al.*, 'limma powers differential expression analyses for RNA-sequencing and microarray studies', *Nucleic Acids Res.*, vol. 43, no. 7, pp. e47–e47, Apr. 2015, doi: 10.1093/nar/gkv007.
- [99] R Core Team, *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing. [Online]. Available: <https://www.R-project.org>
- [100] S. Davis and P. S. Meltzer, 'GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor', *Bioinforma. Oxf. Engl.*, vol. 23, no. 14, pp. 1846–1847, Jul. 2007, doi: 10.1093/bioinformatics/btm254.
- [101] A. Kauffmann *et al.*, 'Importing ArrayExpress datasets into R/Bioconductor', *Bioinforma. Oxf. Engl.*, vol. 25, no. 16, pp. 2092–2094, Aug. 2009, doi: 10.1093/bioinformatics/btp354.
- [102] S. Tweedie *et al.*, 'Genenames.org: the HGNC and VGNC resources in 2021', *Nucleic Acids Res.*, vol. 49, no. D1, pp. D939–D946, Jan. 2021, doi: 10.1093/nar/gkaa980.
- [103] S. Durinck, P. T. Spellman, E. Birney, and W. Huber, 'Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt', *Nat. Protoc.*, vol. 4, no. 8, pp. 1184–1191, 2009, doi: 10.1038/nprot.2009.97.

- [104] Y. Benjamini and Y. Hochberg, 'Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing', *J. R. Stat. Soc. Ser. B Methodol.*, vol. 57, no. 1, pp. 289–300, Jan. 1995, doi: 10.1111/j.2517-6161.1995.tb02031.x.
- [105] F. García-García, 'Methods of functional enrichment analysis in genomic studies', PhD Thesis, 2016.
- [106] W. Viechtbauer, 'Conducting Meta-Analyses in R with the **metafor** Package', *J. Stat. Softw.*, vol. 36, no. 3, 2010, doi: 10.18637/jss.v036.i03.
- [107] R. DerSimonian and N. Laird, 'Meta-analysis in clinical trials', *Control. Clin. Trials*, vol. 7, no. 3, pp. 177–188, Sep. 1986, doi: 10.1016/0197-2456(86)90046-2.
- [108] J. A. C. Sterne and M. Egger, 'Funnel plots for detecting bias in meta-analysis', *J. Clin. Epidemiol.*, vol. 54, no. 10, pp. 1046–1055, Oct. 2001, doi: 10.1016/S0895-4356(01)00377-8.
- [109] E. I. Boyle *et al.*, 'GO::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes', *Bioinformatics*, vol. 20, no. 18, pp. 3710–3715, Dec. 2004, doi: 10.1093/bioinformatics/bth456.
- [110] T. Wu *et al.*, 'clusterProfiler 4.0: A universal enrichment tool for interpreting omics data', *The Innovation*, p. 100141, Jul. 2021, doi: 10.1016/j.xinn.2021.100141.
- [111] M. Ashburner *et al.*, 'Gene Ontology: tool for the unification of biology', *Nat. Genet.*, vol. 25, no. 1, pp. 25–29, May 2000, doi: 10.1038/75556.
- [112] H. Ogata, S. Goto, K. Sato, W. Fujibuchi, H. Bono, and M. Kanehisa, 'KEGG: Kyoto Encyclopedia of Genes and Genomes', *Nucleic Acids Res.*, vol. 27, no. 1, pp. 29–34, Jan. 1999, doi: 10.1093/nar/27.1.29.
- [113] M. J. Alvarez *et al.*, 'Functional characterization of somatic mutations in cancer using network-based inference of protein activity', *Nat. Genet.*, vol. 48, no. 8, pp. 838–847, Aug. 2016, doi: 10.1038/ng.3593.
- [114] L. Garcia-Alonso, C. H. Holland, M. M. Ibrahim, D. Turei, and J. Saez-Rodriguez, 'Benchmark and integration of resources for the estimation of human transcription factor activities', *Genome Res.*, vol. 29, no. 8, pp. 1363–1375, Aug. 2019, doi: 10.1101/gr.240663.118.
- [115] C. Sievert, *Interactive Web-Based Data Visualization with R, plotly, and shiny*. Chapman and Hall/CRC, 2020. [Online]. Available: <https://plotly-r.com>
- [116] H. Wickham, *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York, 2016. [Online]. Available: <https://ggplot2.tidyverse.org>

#### ACKNOWLEDGEMENTS

The authors thank the Principe Felipe Research Center (CIPF) for providing access to the cluster, which is co-funded by European Regional Development Funds (FEDER) in Valencian Community 2014-2020. This work was supported by GV/2020/186.

#### AUTHOR CONTRIBUTIONS

Conceptualization, F.G.G.; methodology, A.L.C., Z.A., R.G.R., M.R.H., and F.G.G.; software, A.L.C., and M.R.H.; validation, A.L.C., M.R.H., R.G.R., and F.G.G.; formal analysis, JF.C.S., R.G.R., and A.L.C.; investigation, A.L.C., Z.A., and F.G.G.; data curation, A.L.C., and M.R.H.; writing—original draft preparation, A.L.C., Z.A., M.R.H., R.G.R., JF.C.S., I.S.S., A.N.A., M.I.V., and F.G.G.; writing—review and editing, A.L.C., Z.A., M.R.H., R.G.R., JF.C.S., I.S.S., A.N.A., M.I.V., and F.G.G.; visualization, A.L.C., R.G.R., M.R.H., and F.G.G.; supervision, Z.A., M.R.H., and F.G.G.; funding acquisition, F.G.G.; project administration, F.G.G. All authors have read and agreed to the published version of the manuscript.

#### COMPETING INTERESTS

The authors declare no competing interests.

**Correspondence** and requests for materials should be addressed to F.G.G.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>